Azacitidine (Azacitidine)

Trade Name : Azacitidine

Accord Healthcare Inc.

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength 100 mg/1

AZACITIDINE Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Azacitidine (Azacitidine) which is also known as Azacitidine and Manufactured by Accord Healthcare Inc.. It is available in strength of 100 mg/1 per ml. Read more

Azacitidine (Azacitidine) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

About GNH

No data

No data

Azacitidine for injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (n n n )nttttttn nn

No data

The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology values, is Azacitidine for injection 75 mg/mn n n daily for 7 days to be administered by subcutaneous injection or intravenous infusion. Premedicate for nausea and vomiting. (n n n )ntttttt n n n
Repeat cycles every 4u00a0weeks (n n n ). After 2 cycles, may increase dose to 100 mg/mn n n if no beneficial effect is seen and no toxicity other than nausea and vomiting has occurred (n n n ). Patients should be treated for a minimum of 4 to 6 cycles. Complete or partial response may require additional treatment cycles (n n n ).n n n
Continue treatment as long as the patient continues to benefit (n n n ).n n n
Monitor patients for hematologic response and for renal toxicity; delay or reduce dosage as appropriate (n n n , n n n , n n n ).n n n

Azacitidine for injection is supplied as lyophilized powder in 100 mg single-dose vials.

Lyophilized powder in 100 mg single-dose vials (n n n ).n n n

No data

Advanced Malignant Hepatic Tumors (n n n ).n n n
Hypersensitivity to Azacitidine or Mannitol (n n n ).n n n

No data

Anemia, Neutropenia and Thrombocytopenia: Monitor complete blood counts (CBC) frequently (n n n ).n n n
Hepatotoxicity: Patients with severe preexisting hepatic impairment are at higher risk for toxicity (n n n ).n n n
Renal Toxicity: Monitor patients with renal impairment for toxicity since azacitidine and its metabolites are primarily excreted by the kidneys (n n n ).n n n
Tumor Lysis Syndrome: Azacitidine for injection may cause fatal or serious tumor lysis syndrome, including in patients with MDS. Assess baseline risk and monitor and treat as appropriate (n n n ).n n n
Embryo-Fetal Risk: Azacitidine for injection can cause fetal harm. Advise females with reproductive potential of the potential risk to a fetus and to avoid pregnancy (n n n ).n n n

The following adverse reactions are described in other labeling sections:
Most common adverse reactions (>30%) by subcutaneous route are: nausea, anemia, thrombocytopenia, vomiting, pyrexia, leukopenia, diarrhea, injection site erythema, constipation, neutropenia and ecchymosis. Most common adverse reactions by intravenous route also included petechiae, rigors, weakness and hypokalemia (n n n ).n nn
To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or n n n n

No data

Lactation: Discontinue nursing taking into consideration the importance of drug to mother (n n n ).n n n

One case of overdose with Azacitidine for injection was reported during clinical trials. A patient experienced diarrhea, nausea, and vomiting after receiving a single intravenous dose of approximately 290 mg/mn n n , almost 4 times the recommended starting dose. The events resolved without sequelae, and the correct dose was resumed the following day. In the event of overdosage, the patient should be monitored with appropriate blood counts and should receive supportive treatment, as necessary. There is no known specific antidote for Azacitidine for injection overdosage.n nn

Azacitidine for injection contains azacitidine, which is a pyrimidine nucleoside analog of cytidine. Azacitidine is 4-amino-1-u03b2-D-ribofuranosyl-s-triazin-2(1H)-one. The structural formula is as follows:u00a0
The empirical formula is Cn n Hn n Nn n On n The molecular weight is 244. Azacitidine is a white to off-white solid. Azacitidine was found to be insoluble in acetone, ethanol, and methyl ethyl ketone; slightly soluble in ethanol/water (50/50), propylene glycol, and polyethylene glycol; sparingly soluble in water, water saturated octanol, 5% dextrose in water, N-methyl-2-pyrrolidone, normal saline and 5% Tween 80 in water; and soluble in dimethylsulfoxide (DMSO).nn
The finished product is supplied in a sterile form for reconstitution as a suspension for subcutaneous injection or reconstitution as a solution with further dilution for intravenous infusion. Vials of Azacitidine for injection contain 100 mg of azacitidine and 100 mg mannitol as a sterile lyophilized powder.

No data

The potential carcinogenicity of azacitidine was evaluated in mice and rats. Azacitidine induced tumors of the hematopoietic system in female mice at 2.2 mg/kg (6.6 mg/mn n n , approximately 8% the recommended human daily dose on a mg/mn n n basis) administered IP three times per week for 52 weeks. An increased incidence of tumors in the lymphoreticular system, lung, mammary gland, and skin was seen in mice treated with azacitidine IP at 2.0u00a0mg/kg (6.0u00a0mg/mn n n , approximately 8% the recommended human daily dose on a mg/mn n n basis) once a week for 50u00a0weeks. A tumorigenicity study in rats dosed twice weekly at 15 or 60u00a0mg/mn n n (approximately 20%-80% the recommended human daily dose on a mg/mn n n basis) revealed an increased incidence of testicular tumors compared with controls.n nn
The mutagenic and clastogenic potential of azacitidine was tested in n n n bacterial systems Salmonella typhimurium strains TA100 and several strains of trpE8, Escherichia coli strains WP14 Pro, WP3103P, WP3104P, and CC103; in n n n forward gene mutation assay in mouse lymphoma cells and human lymphoblast cells; and in an n n n micronucleus assay in mouse L5178Y lymphoma cells and Syrian hamster embryo cells. Azacitidine was mutagenic in bacterial and mammalian cell systems. The clastogenic effect of azacitidine was shown by the induction of micronuclei in L5178Y mouse cells and Syrian hamster embryo cells.n nn
Administration of azacitidine to male mice at 9.9 mg/mn n n (approximately 9% the recommended human daily dose on a mg/mn n n basis) daily for 3 days prior to mating with untreated female mice resulted in decreased fertility and loss of offspring during subsequent embryonic and postnatal development. Treatment of male rats 3 times per week for 11 or 16 weeks at doses of 15-30u00a0mg/mn n n (approximately 20%-40%, the recommended human daily dose on a mg/mn n n basis) resulted in decreased weight of the testes and epididymides, and decreased sperm counts accompanied by decreased pregnancy rates and increased loss of embryos in mated females. In a related study, male rats treated for 16 weeks at 24 mg/mn n n resulted in an increase in abnormal embryos in mated females when examined on day 2 of gestation. n nn

Myelodysplastic Syndromes (MDS)
Study 1 was a randomized, open-label, controlled trial carried out in 53 U.S. sites compared the safety and efficacy of subcutaneous Azacitidine for injection plus supportive care with supportive care alone (u201cobservationu201d) in patients with any of the five FAB subtypes of myelodysplastic syndromes (MDS): refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). RA and RARS patients were included if they met one or more of the following criteria: required packed RBC transfusions; had platelet counts u226450.0 x 10n n n /L; required platelet transfusions; or were neutropenic (ANC <1.0 x 10n n n /L) with infections requiring treatment with antibiotics. Patients with acute myelogenous leukemia (AML) were not intended to be included. Supportive care allowed in this study included blood transfusion products, antibiotics, antiemetics, analgesics and antipyretics. The use of hematopoietic growth factors was prohibited. Baseline patient and disease characteristics are summarized in n n n ; the 2 groups were similar.n nn
Azacitidine for injection was administered at a subcutaneous dose of 75 mg/mn n n daily for 7 days every 4 weeks. The dose was increased to 100 mg/mn n n if no beneficial effect was seen after 2 treatment cycles. The dose was decreased and/or delayed based on hematologic response or evidence of renal toxicity. Patients in the observation arm were allowed by protocol to cross over to Azacitidine for injection if they had increases in bone marrow blasts, decreases in hemoglobin, increases in red cell transfusion requirements, or decreases in platelets, or if they required a platelet transfusion or developed a clinical infection requiring treatment with antibiotics. For purposes of assessing efficacy, the primary endpoint was response rate (as defined in n n n ).n nn
Of the 191 patients included in the study, independent review (adjudicated diagnosis) found that 19 had the diagnosis of AML at baseline. These patients were excluded from the primary analysis of response rate, although they were included in an intent-to-treat (ITT) analysis of all patients randomized. Approximately 55% of the patients randomized to observation crossed over to receive Azacitidine for injection treatment.
The overall response rate (CR + PR) of 15.7% in Azacitidine for injection-treated patients without AML (16.2%u00a0for all Azacitidine for injection randomized patients including AML) was statistically significantly higher than the response rate of 0% in the observation group (p<0.0001) (n n n ). The majority of patients who achieved either CR or PR had either 2 or 3 cell line abnormalities at baseline (79%; 11/14) and had elevated bone marrow blasts or were transfusion dependent at baseline. Patients responding to Azacitidine for injection had a decrease in bone marrow blasts percentage, or an increase in platelets, hemoglobin or WBC. Greater than 90% of the responders initially demonstrated these changes by the 5n n n treatment cycle. All patients who had been transfusion dependent became transfusion independent during PR or CR. The mean and median duration of clinical response of PR or better was estimated as 512 and 330 days, respectively; 75% of the responding patients were still in PR or better at completion of treatment. Response occurred in all MDS subtypes as well as in patients with adjudicated baseline diagnosis of AML.n nn
Patients in the observation group who crossed over to receive Azacitidine for injection treatment (47 patients) had a response rate of 12.8%.
Study 2, a multi-center, open-label, single-arm study of 72 patients with RAEB, RAEB-T, CMMoL, or AML was also carried out. Treatment with subcutaneous Azacitidine for injection resulted in a response rate (CR + PR) of 13.9%, using criteria similar to those described above. The mean and median duration of clinical response of PR or better was estimated as 810 and 430 days, respectively; 80% of the responding patients were still in PR or better at the time of completion of study involvement. In Study 3, another open-label, single-arm study of 48 patients with RAEB, RAEB-T, or AML, treatment with intravenous Azacitidine for injection resulted in a response rate of 18.8%, again using criteria similar to those described above. The mean and median duration of clinical response of PR or better was estimated as 389 and 281 days, respectively; 67% of the responding patients were still in PR or better at the time of completion of treatment. Response occurred in all MDS subtypes as well as in patients with adjudicated baseline diagnosis of AML in both of these studies. Azacitidine for injection dosage regimens in these 2 studies were similar to the regimen used in the controlled study.
Benefit was seen in patients who did not meet the criteria for PR or better, but were considered u201cimproved.u201d About 24% of Azacitidine for injection-treated patients were considered improved, and about 2/3u00a0of those lost transfusion dependence. In the observation group, only 5/83 patients met criteria for improvement; none lost transfusion dependence. In all 3 studies, about 19% of patients met criteria for improvement with a median duration of 195 days.
Study 4 was an international, multicenter, open-label, randomized trial in MDS patients with RAEB, RAEB-T or modified CMMoL according to FAB classification and Intermediate-2 and High risk according to IPSS classification. Of the 358 patients enrolled in the study, 179 were randomized to receive azacitidine plus best supportive care (BSC) and 179 were randomized to receive conventional care regimens (CCR) plus BSC (105 to BSC alone, 49 to low dose cytarabine and 25 to chemotherapy with cytarabine and anthracycline). The primary efficacy endpoint was overall survival.
The azacitidine and CCR groups were comparable for baseline parameters. The median age of patients was 69 years (range was 38-88 years), 98% were Caucasian, and 70% were male. At baseline, 95% of the patients were higher risk by FAB classification: RAEB (58%), RAEB-T (34%), and CMMoL (3%). By IPSS classification, 87% were higher risk: Int-2 (41%), High (47%). At baseline, 32% of patients met WHO criteria for AML.
Azacitidine was administered subcutaneously at a dose of 75u00a0mg/mn n n daily for 7 consecutive days every 28 days (which constituted one cycle of therapy). Patients continued treatment until disease progression, relapse after response, or unacceptable toxicity. Azacitidine patients were treated for a median of 9 cycles (range 1 to 39), BSC only patients for a median of 7 cycles (range 1 to 26), low dose cytarabine patients for a median of 4.5 cycles (range 1 to 15), and chemotherapy with cytarabine and anthracycline patients for a median of 1 cycle (range 1 to 3, i.e. induction plus 1 or 2 consolidation cycles). n nn
In the Intent-to-Treat analysis, patients treated with azacitidine demonstrated a statistically significant difference in overall survival as compared to patients treated with CCR (median survival of 24.5 months vs. 15.0 months; stratified log-rank p=0.0001). The hazard ratio describing this treatment effect was 0.58 (95% CI: 0.43, 0.77).
Kaplan-Meier Curve of Time to Death from Any Cause:
Key: AZA = azacitidine; CCR = conventional care regimens; CI = confidence interval; HR = Hazard Ratio
Azacitidine treatment led to a reduced need for red blood cell transfusions (see n n n ). In patients treated with azacitidine who were RBC transfusion dependent at baseline and became transfusion independent, the median duration of RBC transfusion independence was 13.0u00a0months.n nn

No data

No data

Hepatotoxicity in Patients with Severe Pre-Existing Hepatic Impairmentn- [see Warnings and Precautions (n n n )]n n n
Renal Toxicityn- [see Warnings and Precautions (n n n ) and see Use in Specific Populations (n n n )]n n n
Embryo-Fetal Risk n- [see Warnings and Precautions (n n n ) and see Use in Specific Populations (n n n )]n n n
Advise females of reproductive potential to avoid pregnancy during treatment with Azacitidine for injection. Advise males with female sexual partners of reproductive potential to not father a child and to use effective contraception during treatment with Azacitidine for injection. Advise patients to report pregnancy to their physicians immediately n n n .n nn
Lactationn- [see Use in Specific Populations (n n n )]n n n
Manufactured For:
n Accord Healthcare, Inc.,
n 1009, Slater Road,
n Suite 210-B
n Durham, NC 27703,
nttttUSA.
Manufactured By:
nt Intas Pharmaceuticals Limited,
nt Plot No. 5 to 14 Pharmez,
nt Nr. Village Matoda, Bavla Road,
nt Ta.-Sanand, Dist.
ntt Ahmedabad-382 213,
ntt India.
51 3597 0 720287
Issued: April 2019

Package Label - 100 mg Azacitidine for Injection Label
NDC 16729-n n n -10n nn
Azacitidine for Injection
100 mgn n n n n n Lyophilized Powdern n n n n n Must be dilutedn n n n n n FOR SUBCUTANEOUS AND INTRAVENOUS USE ONLYn n n n n n CAUTION: Cytotoxic Agentn n n n n n Rx onlyu00a0u00a0u00a0u00a0u00a0u00a0One Single Dose Vialn n n n n n

Package Label - 100 mg Azacitidine for Injection Carton
NDC 16729-n n n n n n -10nn nn n nn
Azacitidine for Injection
100 mgn n n n n n Lyophilized Powdern n n n n n Must be dilutedn n n n n n FOR SUBCUTANEOUS AND INTRAVENOUS USE ONLYn n n n n n CAUTION: Cytotoxic Agentn n n n n n Rx onlyu00a0u00a0u00a0u00a0u00a0u00a0One Single Dose Vialn n n n n n

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Get Price

Azacitidine (Azacitidine)

Trade Name : Azacitidine

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what
you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Azacitidine (Azacitidine)

Trade Name : Azacitidine

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Can’t find what
you’re looking for?